Swedish Cooperative Study


Phase N/A Results

Trial Description


Trial Design

Randomized, double-blind, placebo-controlled trial of 505 patients at 6 centers.

Patient Involvement

Patients were randomized to receive treatment with acetylsalicylic acid (ASA) 1.5 g or placebo. Patients were examined by the clinical investigators at 1 and 3 months after entry and every 3 months thereafter for 2 years.


Type Measure Time Frame Safety Issue
Primary Recurrent stroke or death.
Secondary Myocardial infarction and transient ischemic attack.


Farmos Group AB, Sweden